Tianjin Xinyi Shangde Biomedical Technology

Tianjin Xinyi Shangde Biomedical Technology is a biotechnology research and development company based in Tianjin, China. Established in 2021, it operates as a core innovative R&D subsidiary of Shanghai Xinyi Pharmaceutical, which is part of the Shanghai Pharmaceuticals Holding (SPH) group. The company focuses on the discovery and development of high-quality innovative small molecule therapeutics, particularly in the fields of cardiovascular health, oncology, and metabolic disorders. Xinyi Shangde serves as a strategic R&D hub within the SPH ecosystem, leveraging advanced medicinal chemistry and pharmacological screening to advance candidates from discovery through clinical stages. Its pipeline features several Class 1 innovative drugs, including the renin inhibitor SPH3127, which is currently in late-stage clinical development for hypertension. By utilizing the manufacturing and commercial strengths of its parent organization, the company aims to address significant unmet medical needs in the Chinese pharmaceutical market.